| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre … R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ... The lancet oncology 13 (3), 239-246, 2012 | 5964 | 2012 |
| Screening for epidermal growth factor receptor mutations in lung cancer R Rosell, T Moran, C Queralt, R Porta, F Cardenal, C Camps, M Majem, ... New England Journal of Medicine 361 (10), 958-967, 2009 | 2946 | 2009 |
| EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non–small cell lung cancer: a retrospective analysis JF Gainor, AT Shaw, LV Sequist, X Fu, CG Azzoli, Z Piotrowska, ... Clinical cancer research 22 (18), 4585-4593, 2016 | 1111 | 2016 |
| Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as … R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ... Lancet Oncol 13 (3), 239-246, 2012 | 626 | 2012 |
| RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer MJ Niederst, LV Sequist, JT Poirier, CH Mermel, EL Lockerman, ... Nature communications 6 (1), 6377, 2015 | 579 | 2015 |
| Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer H Yasuda, E Park, CH Yun, NJ Sng, AR Lucena-Araujo, WL Yeo, ... Science translational medicine 5 (216), 216ra177-216ra177, 2013 | 546 | 2013 |
| Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 K Ohashi, LV Sequist, ME Arcila, T Moran, J Chmielecki, YL Lin, Y Pan, ... Proceedings of the National Academy of Sciences 109 (31), E2127-E2133, 2012 | 509 | 2012 |
| Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non–small-cell lung cancer E Felip, R Rosell, JA Maestre, JM Rodríguez-Paniagua, T Morán, ... Journal of Clinical Oncology 28 (19), 3138-3145, 2010 | 453 | 2010 |
| Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung … M Taron, Y Ichinose, R Rosell, T Mok, B Massuti, L Zamora, JL Mate, ... Clinical cancer research 11 (16), 5878-5885, 2005 | 391 | 2005 |
| Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non–small-cell lung cancer patients with EGFR mutations R Rosell, MA Molina, C Costa, S Simonetti, A Gimenez-Capitan, ... Clinical Cancer Research 17 (5), 1160-1168, 2011 | 356 | 2011 |
| Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients H Cortes-Funes, C Gomez, R Rosell, P Valero, C Garcia-Giron, A Velasco, ... Annals of oncology 16 (7), 1081-1086, 2005 | 283 | 2005 |
| The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in … C Costa, MA Molina, A Drozdowskyj, A Giménez-Capitán, ... Clinical cancer research 20 (7), 2001-2010, 2014 | 276 | 2014 |
| Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial N Karachaliou, C Mayo-de las Casas, C Queralt, I de Aguirre, B Melloni, ... JAMA oncology 1 (2), 149-157, 2015 | 266 | 2015 |
| Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression R Rosell, L Perez-Roca, JJ Sanchez, M Cobo, T Moran, I Chaib, ... PloS one 4 (5), e5133, 2009 | 238 | 2009 |
| Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study J Glasbey, A Ademuyiwa, A Adisa, E AlAmeer, AP Arnaud, F Ayasra, ... The Lancet Oncology 22 (11), 1507-1517, 2021 | 233 | 2021 |
| Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis M Duruisseaux, A Martínez-Cardús, ME Calleja-Cervantes, S Moran, ... The Lancet Respiratory Medicine 6 (10), 771-781, 2018 | 184 | 2018 |
| Characteristics of Lung Cancers Harboring NRAS Mutations K Ohashi, LV Sequist, ME Arcila, CM Lovly, X Chen, CM Rudin, T Moran, ... Clinical Cancer Research 19 (9), 2584-2591, 2013 | 174 | 2013 |
| Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999–2007: results of EUROCARE-5 C Lepage, R Capocaccia, M Hackl, V Lemmens, E Molina, ... European Journal of Cancer 51 (15), 2169-2178, 2015 | 158 | 2015 |
| Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations I Garcia-Olivé, E Monsó, F Andreo, J Sanz-Santos, M Taron, ... European Respiratory Journal 35 (2), 391-395, 2010 | 152 | 2010 |
| Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non–small cell lung cancer MA Molina-Vila, J Bertran-Alamillo, A Gascó, C Mayo-de-las-Casas, ... Clinical Cancer Research 20 (17), 4647-4659, 2014 | 146 | 2014 |
